DCGI has granted emergency use approval for use of ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms

Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Phase III clinical trial studies reported that a larger proportion of patients when administered subcutaneously with Virafin turned out to be RT-PCR negative by day 7, apart from faster recovery as compared to other anti-viral agents.

Zydus Cadila also known Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India primarily engaged in the manufacture of generic drugs.

RECENT UPDATES

Digital Brand Identity Manual

The DBIM defines key elements of a consistent digital identity, including visual identities such as logos, color palettes, typography, and imagery, as well as verbal

Read More »